PT - JOURNAL ARTICLE AU - Hong, David AU - Kwon, Woochan AU - Lee, Seung Hun AU - Shin, Doosup AU - Kim, Hyun Kuk AU - Lee, Kwan Yong AU - Choo, Eun Ho AU - Kim, Sung Eun AU - Hong, Young Joon AU - Ahn, Young Keun AU - Jeong, Myung Ho AU - Ha, Junho AU - Hong, Minseok AU - Choi, Ki Hong AU - Park, Taek Kyu AU - Yang, Jeong Hoon AU - Song, Young Bin AU - Hahn, Joo-Yong AU - Choi, Seung-Hyuk AU - Gwon, Hyeon-Cheol AU - Lee, Joo Myung AU - , TI - Intravascular Imaging-Guided Versus Angiography-Guided PCI: Systematic Review and Meta-analysis of 24 Randomized Controlled Trials AID - 10.1101/2023.10.23.23297425 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.23.23297425 4099 - http://medrxiv.org/content/early/2023/10/24/2023.10.23.23297425.short 4100 - http://medrxiv.org/content/early/2023/10/24/2023.10.23.23297425.full AB - Objective To evaluate comparative prognosis between intravascular imaging-guided PCI and angiography-guided PCI using a comprehensive meta-analysis including all previous randomized controlled trials.Design Systematic review and meta-analysis of randomized controlled trials.Data Sources Target trials were selected by a systematic electronic search strategy in the PubMed, EMBASE, and Cochrane databases from their inception to Sep, 2023.Study Selection Published randomized controlled trials which compared clinical outcomes between intravascular imaging-guided and angiography-guided PCI were included.Main Outcome and Measures Major adverse cardiac events (MACE), all-cause death, myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis.Review Methods Random-effects model was used to calculate pooled relative risk (RR) and 95% confidence interval (CI) between intravascular imaging-guided and angiography-guided PCI. Heterogeneity was assessed by I2 values.Results Among a total of 14,037 patients (7,383 in intravascular imaging-guided PCI and 6,654 in angiography-guided PCI groups), intravascular imaging-guided PCI was associated with a lower risk of MACE than angiography-guided PCI (RR, 0.75; 95% CI, 0.67 to 0.84; P<0.001; I2, 18.9%), driven by lower risk of MI (RR, 0.83; 95% CI, 0.70 to 0.97; P=0.019; I2, 0.0%), TVR (RR, 0.70; 95% CI, 0.61 to 0.79; P<0.001; I2, 0.0%), and stent thrombosis (RR, 0.50; 95% CI, 0.32 to 0.78; P=0.002; I2, 0.0%). There was no difference in the risk of all-cause death (RR, 0.82; 95% CI, 0.67 to 1.01; P=0.068; I2, 0.0%), however, trials with 2nd generation drug-eluting stent (DES) showed significant reduction of all-cause death following intravascular imaging-guided PCI (RR, 0.77; 95% CI, 0.61 to 0.95; P=0.018; I2, 0.0%).Conclusions Compared to angiography-guided PCI, intravascular imaging-guided PCI was associated with a reduced the risk of MACE, by lowering the risks of MI, TVR, and stent thrombosis. Pooled analysis of trials with 2nd generation DES showed significantly lower risk of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI.Systematic Review Registration PROSPERO, CRD42023402677Due to limited sample size, previous randomized controlled trials (RCTs) were not able to show significant differences in the risks of hard clinical events such as death, myocardial infarction (MI), or stent thrombosis between intravascular imaging-guided percutaneous coronary intervention (PCI) and angiography-guided PCI.Although previous meta-analyses showed that intravascular imaging-guided PCI resulted in a lower risk of death or MI than angiography-guided PCI, inclusion of both observational studies and RCTs caused heterogeneity and lowered the evidence level of the results.The current meta-analysis exclusively included 24 RCTs and showed that intravascular imaging-guided PCI significantly reduced the risk of major adverse cardiac events (MACE), compared with angiography-guided PCI.It should be noted that intravascular imaging-guided PCI reduced not only the risk of target-vessel revascularization but also the risks of hard clinical events such as MI and stent thrombosis.Competing Interest StatementDr. Joo Myung Lee received an Institutional Research Grant from Abbott Vascular, Boston Scientific, Philips Volcano, Terumo Corporation, Zoll Medical, and Donga-ST. Prof. Joo-Yong Hahn received an Institutional Research Grant from National Evidence-based Healthcare Collaborating Agency, Ministry of Health & Welfare, Korea, Abbott Vascular, Biosensors, Boston Scientific, Daiichi Sankyo, Donga-ST, Hanmi Pharmaceutical, and Medtronic Inc. Prof. Hyeon-Cheol Gwon received an Institutional Research Grant from Boston Scientific, Genoss, and Medtronic Inc. All other authors declare that there are no competing interests to declare.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=402677 Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study-level meta-analysis used the published trials data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesOriginal data used in the current meta-analysis including the analytic codes will be shared upon reasonable request. Any relevant inquiry should be emailed to Dr. Joo Myung Lee (Email: drone80{at}hanmail.net). The lead author (JML) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted, and that any discrepancies from the study as planned have been explained. CIconfidence intervalDESdrug-eluting stentIVUSintravascular ultrasoundMACEmajor adverse cardiac eventsMImyocardial infarctionOCToptical coherence tomographyORodds ratioPCIpercutaneous coronary interventionRCTrandomized controlled trialTVRtarget vessel revascularization